There is a question I’m hearing more and more, from clients and peers: “Can I have a psychedelic journey while on a GLP-1?” The worry is usually that delayed gastric emptying will delay onset or prolong the journey, and the conversation jumps to routes that avoid the gut, or to planning around a dose. Basically, tricks and workarounds, with a growing amount of information behind them. There are real answers, and I’ll give the short version below. But there’s more to consider before making a plan. There always is.
The first question is not how can we, but should we. Is this person stable, resourced, and balanced in all five of their bodies: the physical, the psychological, the emotional, the energetic, and the spiritual? That is the first question of preparedness for any journey, and it weighs more when someone is already in another course that works on mind, body, and energy. Depending on the intention, that may not be the time to layer psychedelic expansion on top.
Five bodies, one load
A GLP-1 touches every one of them. Physically, appetite, digestion, thirst, and energy change. Psychologically, the food noise goes quiet, and so does some of the wanting in general, which can be a relief or feel flat. Emotionally, a lot comes up around the body, food, shame, and self-worth. Energetically, many people run on little. Spiritually, a changed relationship with hunger and desire is not small. For many it becomes an initiation of its own.
A psychedelic journey touches the same five bodies. Doing two big processes at once may overtax a system already carrying a great deal. That isn’t a claim of proven harm. It’s a caution, and a question worth asking before the ceremony instead of after.
I took a GLP-1 myself at a low dose for three months to manage blood sugar. It worked, but it was far more complicated than I expected, emotionally and physically. It changed my sense of drive and my self-image. It can also be a secretive, shame-filled time, even though so many people are on them.
Running on a deficit
GLP-1 is a hormone our own gut releases after we eat, one of the signals that says enough. The first drug in this class came from the saliva of the Gila monster, a lizard that eats large, infrequent meals. It makes sense that an animal that eats like that would carry something that slows digestion and quiets the urge to eat. In people, the whole system slows, and there is less need to eat, drink, and consume.
These medications create a caloric deficit, which is the point. What gets discussed less is the nutrition that goes missing. In one small study of 69 people, only 43 percent met their protein needs, and potassium, magnesium, iron, and vitamin D fell well below recommendations. It’s small and self-reported, but I’d guess it’s common. Many people also get these medications online with little screening or oversight, often telling no one. Some keep eating well. Others barely eat. So I screen for it: how much are you actually eating and drinking?
Psychedelics are physically demanding. Ayahuasca raises blood pressure, heart rate, and stress hormones, and so do psilocybin and most others. There is an energetic cost too, palpable at the end of a session, when people are often deeply exhausted. On top of an existing deficit, that is a lot to ask.
GLP-1s also quiet thirst, and dehydration and kidney injury are recognized in people taking them. With MDMA, dehydration from body heat is the likelier danger.
Integration asks for what the medication quiets
Integration is mostly ordinary: nourishing food, water, sleep, rest, and feeling what comes up. A body in a deficit has less to rebuild with. A GLP-1 dulls the urge to eat and drink, and seems to reach further, toward the urge to reach for things at all. A large observational study found much lower odds of alcohol, opioid, nicotine, and cocaine use disorders in GLP-1 users. It can’t prove cause, but it suggests the quiet isn’t only about food. Someone coming out of a journey, tender and depleted, may feel no hunger or thirst to prompt them to nourish themselves.
What I’ve seen
I have worked with a handful of people on GLP-1s. A couple did not tell me, although I always ask, and were still within their dosing period. Theirs were the “worst” outcomes: little to no engaging psychedelic experience, large fear and confusion, nausea and vomiting, and a mind-altering state without the usual hallmarks. A few others had skipped a dose or thought they were far enough out. Every session was harder than average in the same ways: more fear, reactivity, and confusion, and little immersive content.
It’s a small group, and an observation, not data, but it matches what other facilitators tell me. If you take one of these medications, please tell whoever is sitting with you. Nobody can plan around what they don’t know.
What season are we in?
I mean the season of life, not only where someone is in their medication. Is this the season for a GLP-1 and psychedelic expansion at the same time, or does each deserve its own? Often they do. If it’s a season, I’d rather wait it out, find stability and a sense of self, and then journey.
The questions I ask instead of how
How are you eating, drinking, and sleeping? What is your emotional ground right now? Who will be there the week after? Is this the season for it? If the honest answers are steady, nourished, and supported, we can talk about how. If not, the better medicine may be everything around the journey.
If we talk about how
Almost none of this has been studied in people on GLP-1s, so much of it is practitioner reports and reasoning, and I’ll say which is which. GLP-1s slow gastric emptying, and practitioners report onset two to six hours out instead of 30 to 45 minutes, weaker effects, sudden drop-offs, sometimes nothing. A delay has its own risk: someone who feels nothing and takes more can end up with both doses at once.
Timing matters too. Most of these medications are dosed weekly. Semaglutide’s half-life is about a week, and tirzepatide’s about five days. A drug is usually considered meaningfully cleared after four half-lives, when about 94 percent is gone. That’s roughly four weeks for semaglutide and three for tirzepatide, so I think in weeks, not days, and one skipped dose isn’t enough.
Not everything depends on the gut. Other substances take other pathways, and a slow stomach may affect them differently, or not at all. Vaporized DMT is absorbed through the lungs and works in seconds. Ketamine can be injected, taken through the nose, or held under the tongue, and injected ketamine is absorbed far more completely than swallowed, with or without a GLP-1. Rectal and other routes exist too, but how any of them behave in people on GLP-1s is mostly unknown.
Mushrooms are where most delay reports come from, so lemon tek comes up: grind them, soak in citrus, drink it. Many believe the acid converts psilocybin to psilocin first, but enzymes in the intestinal lining do that, after the stomach, so the lemon more likely does extraction. In my experience, straining out the mushroom reduces the nausea the mushroom itself causes; unstrained, there seems to be less reduction. That’s a real benefit, but a different problem from a GLP-1’s. The rest is anecdotal, and PsychonautWiki says there’s no research behind it. A 2026 trial found that swallowing already-converted psilocin didn’t speed up peak intensity, so conversion isn’t what sets the clock. The likelier bottleneck is a slow stomach and gut, though that’s my reading, not a finding. I lemon tek myself and haven’t found it a reliable workaround.
What we can do instead
If the answer is not yet, there is plenty of good work to do in the meantime. We can prepare by balancing the five bodies as each needs and building awareness in them as a baseline. We can work through breath, sound, energy work, and movement, and with intention, mantra, and meditation. In my experience these are more nourishing and far less taxing than a psychedelic, and they build the capacity a journey asks for later, though that is experience, not a finding. The evidence for the practices themselves is encouraging but modest: a meta-analysis of 12 trials found small to moderate drops in stress, anxiety, and depression with breathwork, and a review of 51 trials found similar benefits from mantra meditation, though few studies were high quality. Sound work and Reiki have less evidence, with modest benefits for anxiety and quality of life. Choose gentle forms. Not every breath practice is easy on the body.
When the answer might be yes
The reason someone is on it matters. For a goal weight, waiting until they’ve finished is a reasonable ask. For a chronic condition like type 2 diabetes, it isn’t a phase, and “wait until you’re off” doesn’t help; the workarounds above may be the right conversation. A short break may be possible and cause no harm in some cases, but that is for their doctor to decide, with a plan for stopping and restarting. After a long gap, label guidance says to restart lower.
There are also seasons when the answer changes. Someone near the end of life may have a deeply taxed body and still want to meet that time with a psychedelic. In a trial of 29 people with cancer-related anxiety and depression, psilocybin-assisted therapy brought large reductions that held for years in those followed up. And a GLP-1 on its own can reduce drinking, as one small trial of 50 adults with alcohol use disorder found, so pairing it with intentional psychedelic work for substance use, binge drinking, and other dependencies is a fair question. I haven’t found studies of the two together, so I can’t call it evidence yet. None of this is my specialty, or the intention of most sessions I lead. But it shows that should we has no single answer. It depends on the person, the season, and what they hope for, and it belongs with their medical team.
A gentle no, or a not yet
I’m not currently taking people on GLP-1s into deep psychedelic spaces. For now. A GLP-1 is deep work already, and adding a powerful substance on top is unnecessary and may be harmful in ways we haven’t learned yet. I’m glad to support people in other ways in the meantime. And please don’t change or skip your medication for a ceremony without talking to your prescriber first.
How a no lands matters. Many people on these medications are already working through shame and rejection, so I say it with care and a real invitation for later. A not yet is not a verdict on the person. It’s an invitation to come back.
